Archive | June 2016

Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry

Bhaskar Chanda Stem Cell Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.

from Cell Stem Cell http://ift.tt/29bapVK
via Bhaskar Chanda UHN

Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry

Bhaskar Chanda Stem Cell Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.

from Cell Stem Cell http://ift.tt/29bapVK
via Bhaskar Chanda UHN

Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry

Bhaskar Chanda Stem Cell Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.

from Cell Stem Cell http://ift.tt/29bapVK
via Bhaskar Chanda UHN

Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry

Bhaskar Chanda Stem Cell Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.

from Cell Stem Cell http://ift.tt/29bapVK
via Bhaskar Chanda UHN

Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry

Bhaskar Chanda Stem Cell Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.

from Cell Stem Cell http://ift.tt/29bapVK
via Bhaskar Chanda UHN

Generation of a Nonhuman Primate Model of Severe Combined Immunodeficiency Using Highly Efficient Genome Editing

Bhaskar Chanda Stem Cell In this article, Sato and colleagues describe the generation of an immunodeficient nonhuman primate model. By optimizing ZFN and TALEN targeting of the IL2RG gene in marmoset fibroblasts and embryos, and using blastomere splitting as a proxy for rapid genome editing to reduce mosaicism, the authors generated founder animals with an immunodeficient phenotype similar to that of human patients with X-SCID.

from Cell Stem Cell http://ift.tt/29baMQ2
via Bhaskar Chanda UHN

Generation of a Nonhuman Primate Model of Severe Combined Immunodeficiency Using Highly Efficient Genome Editing

Bhaskar Chanda Stem Cell In this article, Sato and colleagues describe the generation of an immunodeficient nonhuman primate model. By optimizing ZFN and TALEN targeting of the IL2RG gene in marmoset fibroblasts and embryos, and using blastomere splitting as a proxy for rapid genome editing to reduce mosaicism, the authors generated founder animals with an immunodeficient phenotype similar to that of human patients with X-SCID.

from Cell Stem Cell http://ift.tt/29baMQ2
via Bhaskar Chanda UHN

Generation of a Nonhuman Primate Model of Severe Combined Immunodeficiency Using Highly Efficient Genome Editing

Bhaskar Chanda Stem Cell In this article, Sato and colleagues describe the generation of an immunodeficient nonhuman primate model. By optimizing ZFN and TALEN targeting of the IL2RG gene in marmoset fibroblasts and embryos, and using blastomere splitting as a proxy for rapid genome editing to reduce mosaicism, the authors generated founder animals with an immunodeficient phenotype similar to that of human patients with X-SCID.

from Cell Stem Cell http://ift.tt/29baMQ2
via Bhaskar Chanda UHN

Generation of a Nonhuman Primate Model of Severe Combined Immunodeficiency Using Highly Efficient Genome Editing

Bhaskar Chanda Stem Cell In this article, Sato and colleagues describe the generation of an immunodeficient nonhuman primate model. By optimizing ZFN and TALEN targeting of the IL2RG gene in marmoset fibroblasts and embryos, and using blastomere splitting as a proxy for rapid genome editing to reduce mosaicism, the authors generated founder animals with an immunodeficient phenotype similar to that of human patients with X-SCID.

from Cell Stem Cell http://ift.tt/29baMQ2
via Bhaskar Chanda UHN

Generation of a Nonhuman Primate Model of Severe Combined Immunodeficiency Using Highly Efficient Genome Editing

Bhaskar Chanda Stem Cell In this article, Sato and colleagues describe the generation of an immunodeficient nonhuman primate model. By optimizing ZFN and TALEN targeting of the IL2RG gene in marmoset fibroblasts and embryos, and using blastomere splitting as a proxy for rapid genome editing to reduce mosaicism, the authors generated founder animals with an immunodeficient phenotype similar to that of human patients with X-SCID.

from Cell Stem Cell http://ift.tt/29baMQ2
via Bhaskar Chanda UHN